New Delhi, May 30 -- Millions of breast cancer patients could now safely skip chemotherapy and be treated with hormone therapy alone. This is possible as scientists developed a DNA or gene test that can differentiate between patients who are likely to benefit from the treatment and those who are not, a clinical trial has shown.

According to a trial conducted by University College London (UCL), a revolutionary new genomic test can reliably identify which women will benefit from chemotherapy and which will not.

The press note by Eurekalert states that Chemotherapy is regularly offered to people with early‑stage breast cancer that has spread from the breast to nearby lymph nodes, as it lowers the risk of the disease returning.

Howev...